Posted by Michael Wonder on 10 Jun 2020
Akcea announces approval for reimbursement of Tegsedi (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
8 June 2020 - Tegsedi is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home subcutaneous injection.
Akcea Therapeutics today announced that AIFA, or The Italian Medicines Agency, has granted approval for the reimbursement of Tegsedi (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis.
The Italian Medicines Agency's approval of reimbursement for Tegsedi was based on results from the Phase 3 NEURO-TTR study in patients with hATTR amyloidosis with symptoms of polyneuropathy.
